This year’s PSA: The Pharmaceutical Strategy Conference will explore how various players in the biopharmaceutical ecosystem can gain the most value from scientific and business model innovation. It will also examine what large investors want from large pharma, and at the other end of the value chain, what venture capitalists and entrepreneurs learned from the bloodbath of the past few years. PSA offers case studies about today’s top biopharma issues from CEOs, Senior R&D and Senior Business Development executives. Not only will they share lessons learned, and practical advice for sealing a deal, but these key opinion leaders will debate the issues that are top of mind — from enhancing R&D productivity to doing more with less in Business Development. This year, the Pharmaceutical Strategy Conference will take place September 23-25 in New York.